NYLIM
MDGL icon

New York Life Investment Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

New York Life Investment Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.05M Buy
2,013
+627
+45% +$300K 0.01% 658
2025
Q4 		$807K Sell
1,386
-224
-14% -$114K 0.01% 655
2025
Q3 		$738K Sell
1,610
-43
-3% -$16K 0.01% 714
2025
Q2 		$500K Sell
1,653
-12
-0.7% -$3.58K ﹤0.01% 761
2025
Q1 		$551K Buy
+1,665
New +$547K 0.01% 767

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

New York Life Investment Management's MDGL Position: Q1 2026 in Review

New York Life Investment Management increased its Madrigal Pharmaceuticals (MDGL) stake by 45% in Q1 2026, buying an estimated $300K and bringing the position to 2,013 shares worth $1.05M. The position accounts for 0.01% of the portfolio, ranked #658.

New York Life Investment Management first reported a position in MDGL in Q1 2025 and has held it in 5 quarters since. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • New York Life Investment Management held 2,013 shares of Madrigal Pharmaceuticals worth $1.05M as of Q1 2026.
  • New York Life Investment Management bought 627 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $300K.
  • Madrigal Pharmaceuticals made up 0.01% of New York Life Investment Management's portfolio in Q1 2026, its #658 holding.
  • New York Life Investment Management first reported a position in Madrigal Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on New York Life Investment Management's 13F filing for Q1 2026, filed 7 May 2026.